No one said it would be a cinch reducing a mammoth taxpayer subsidized drug benefit.
The Medicare Part B benefit pays for drugs administered in doctors’ offices and outpatient facilities. It weighed in at $26 billion in 2015 and is growing at 9 percent a year.
Last year, the Medicare agency got clobbered with objections from thousands of interest groups and beneficiaries when it proposed a multifaceted demonstration from its innovation center to test alternative drug payment structures.
It eventually withdrew the demo from consideration. The withdrawal was one of the few things Republicans and Democrats agreed on last year.
Congress’ Medicare advisers—the Medicare Payment Advisory Commission (MedPAC)—has taken up the issue throughout the years.
Now MedPAC is at it again, molding a package of recommendations. The centerpiece is an option to get lower-priced drugs from private vendors, called the Drug Value Program.
However, an earlier vendor program, called the Competitive Acquisition Program, or CAP, fizzled in 2008 for lack of interest and/or skittishness from vendors and doctors. Just one vendor participated.
The new program would be informed by lessons learned from CAP—structured to increase vendors' negotiating power and give providers shared savings, MedPAC said.
The commissioners’ game plan is to hash out the recommendations in March, vote in April, and present them to Congress in June.
It’s uncertain how the new Congress will receive the final recommendations.
MedPAC’s recommendations on revamping the prescription-based outpatient Part D drug benefit approved last spring have so far been snubbed.
But one thing is for certain: Interest groups like drugmakers, beneficiary advocates, and cancer centers, will fight like lions against any Part B revamping they don’t regard as in their best interest.
Read more on MedPAC’s latest ideas here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)